JAMA network open

Glucagon-Like Peptide-1 Drugs and Risk of Fragile Bone Fractures in Type 2 Diabetes

Updated

Abstract

Obesity, type 2 diabetes, and weight loss could increase the risk of fragility fractures.

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly prescribed medications.
  • The effects of GLP-1 RAs on bone health and fracture risk remain unclear.
  • Increased fragility fracture risk is associated with obesity and type 2 diabetes.
  • Weight loss may also contribute to higher fragility fracture risk.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free